

# CITATION REPORT

List of articles citing

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

DOI: 10.2119/2006-00085.baechler  
Molecular Medicine, 2007, 13, 59-68.

**Source:** <https://exaly.com/paper-pdf/42481129/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
240	Defining a new molecular basis of systemic lupus erythematosus through transcriptional profiling. <b>2007</b> , 3, 913-23		1
239	Pathogenesis of myositis in children. <b>2007</b> , 19, 487-91		12
238	A gene expression approach to study perturbed pathways in myositis. <b>2007</b> , 19, 536-41		30
237	Bibliography. Current world literature. Systemic lupus erythematosus and Sjögren's syndrome. <b>2007</b> , 19, 499-508		
236	Microarray-based identification of novel biomarkers in IL-1-mediated diseases. <b>2007</b> , 19, 623-32		31
235	Involvement of dendritic cells in autoimmune diseases in children. <b>2007</b> , 5, 16		3
234	C-reactive protein and systemic lupus erythematosus. <b>2008</b> , 59, 1814-20		82
233	How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. <b>2008</b> , 223, 39-59		57
232	Developments in the scientific and clinical understanding of inflammatory myopathies. <b>2008</b> , 10, 220		15
231	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. <b>2008</b> , 371, 2201-12		311
230	Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease. <b>2008</b> , 144, 1379-82		1
229	Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. <b>2008</b> , 20, 669-74		23
228	Current world literature. <b>2008</b> , 20, 729-35		
227	Current world literature. <b>2008</b> , 21, 615-24		
226	[Recent research developments in polymyositis/dermatomyositis]. <b>2008</b> , 31, 85-92		
225	Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. <b>2008</b> , 144, 1341-9		40
224	Genomics and proteomics: Applications in autoimmune diseases. <b>2009</b> , 2, 39-48		4

223	Gene-expression profiling in rheumatic disease: tools and therapeutic potential. <b>2009</b> , 5, 257-65		30
222	A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. <b>2009</b> , 132, 3353-65		168
221	Interferon alpha and neuromuscular disorders. <b>2009</b> , 207, 3-17		39
220	Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. <b>2009</b> , 23, 665-78		82
219	Hypothesis: sarcoidosis is a STAT1-mediated disease. <b>2009</b> , 132, 174-83		55
218	Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. <b>2009</b> , 60, 1815-24		95
217	Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. <b>2009</b> , 60, 3436-46		157
216	Genetic risk and protective factors for the idiopathic inflammatory myopathies. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 287-94	4.9	16
215	The inflammatory milieu in idiopathic inflammatory myositis. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 295-301	4.9	18
214	Disease-associated pathophysiologic structures in pediatric rheumatic diseases show characteristics of scale-free networks seen in physiologic systems: implications for pathogenesis and treatment. <b>2009</b> , 2, 9		13
213	Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. <b>2009</b> , 10, 210-8		35
212	Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment. <b>2009</b> , 11, 361-74		12
211	Type I IFNs and their role in the development of autoimmune diseases. <b>2009</b> , 8, 459-72		31
210	Clinical applications of IFN- $\beta$ blockade in systemic lupus erythematosus. <b>2009</b> , 4, 617-619		
209	Defining TNF- $\beta$ and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease. <b>2010</b> , 88, 1065-79		14
208	Update on the assessment of children with juvenile idiopathic inflammatory myopathy. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 204-12	4.9	3
207	Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. <b>2010</b> , 157, 653-7		29
206	Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. <b>2010</b> , 62, 1446-51		69

205	Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis. <b>2010</b> , 62, 1744-54	22
204	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?. <b>2010</b> , 62, 2619-22	2
203	Immunopathogenesis of juvenile dermatomyositis. <b>2010</b> , 41, 581-92	37
202	Assessing the human immune system through blood transcriptomics. <b>2010</b> , 8, 84	178
201	Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. <b>2010</b> , 11, 269-78	54
200	Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. <b>2010</b> , 1184, 134-53	145
199	Safety, Tolerability, and Immunogenicity of Interferons. <b>2010</b> , 3, 1162-1186	17
198	The type I interferon system in idiopathic inflammatory myopathies. <b>2010</b> , 43, 239-43	20
197	Type I interferon system activation and association with disease manifestations in systemic sclerosis. <b>2010</b> , 69, 1396-402	124
196	Association of IRF5 polymorphisms with activation of the interferon alpha pathway. <b>2010</b> , 69, 611-7	48
195	Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. <b>2010</b> , 49, 156-66	26
194	Type I interferons: crucial participants in disease amplification in autoimmunity. <b>2010</b> , 6, 40-9	178
193	Management of the Connective Tissue Diseases of Childhood. <b>2010</b> , 249-274	
192	Cytokine-induced monocyte characteristics in SLE. <b>2010</b> , 2010, 507475	18
191	Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway. <b>2010</b> , 84, 9181-9	20
190	Sensors of the innate immune system: their link to rheumatic diseases. <b>2010</b> , 6, 146-56	68
189	A genomic approach to human autoimmune diseases. <b>2010</b> , 28, 535-71	123
188	A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. <b>2010</b> , 62, 427-36	62

187	Current insights in polymyositis and dermatomyositis. <b>2010</b> , 1, 22-32	4
186	Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. <b>2010</b> , 12, R179	12
185	Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. <b>2010</b> , 12, R11	87
184	Type 1 interferons and myositis. <b>2010</b> , 12 Suppl 1, S4	40
183	Type I interferon pathway in adult and juvenile dermatomyositis. <b>2011</b> , 13, 249	81
182	Polymyositis and dermatomyositis: pathophysiology. <b>2011</b> , 37, 159-71, v	32
181	Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. <b>2011</b> , 7, 343-54	136
180	JUVENILE DERMATOMYOSITIS. <b>2011</b> , 375-413	13
179	Idiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis. <b>2011</b> ,	1
178	An update on pathogenic mechanisms of inflammatory myopathies. <b>2011</b> , 23, 579-84	25
177	Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. <b>2011</b> , 28, 357-67	32
176	Pathogenesis of dermatomyositis: role of cytokines and interferon. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 225-32	4-9 37
175	Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. <b>2011</b> , 59, 780-90	18
174	Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. <b>2011</b> , 147, 831-5	16
173	Musculoskeletal System: Articular Disease, Bone Metabolism. <b>2011</b> , 921-942	
172	Paediatric rheumatic disease: Defining clinically inactive disease in juvenile dermatomyositis. <b>2012</b> , 8, 638-9	5
171	HTLV-1 infection: what determines the risk of inflammatory disease?. <b>2012</b> , 20, 494-500	20
170	Juvenile dermatomyositis: A review of clinical features and management. <b>2012</b> , 7, 80-86	4

169	Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. <b>2012</b> , 64, 4078-86	61
168	The multifaceted balance of TNF- $\alpha$ and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. <b>2012</b> , 90, 1295-309	42
167	Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes. <b>2012</b> , 13, 593-604	53
166	The genetics of type I interferon in systemic lupus erythematosus. <b>2012</b> , 24, 530-7	93
165	An interferon response gene expression signature is activated in a subset of medulloblastomas. <b>2012</b> , 5, 297-304	7
164	Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. <b>2012</b> , 14, R48	23
163	Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia. <b>2012</b> , 7, e38449	17
162	Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. <b>2012</b> , 167, 391-404	101
161	Paraneoplastic dermatomyositis associated with metastatic melanoma. <b>2012</b> , 10, 63-4	1
160	Paraneoplastische Dermatomyositis bei metastasiertem malignen Melanom. <b>2012</b> , 10, 63-64	3
159	The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. <b>2012</b> , 166, 971-5	89
158	Targeted immunotherapy trials for idiopathic inflammatory myopathies. <b>2013</b> , 260, 368-85	1
157	Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. <b>2013</b> , 88, 83-105	118
156	Innate immune processes in lupus erythematosus. <b>2013</b> , 147, 216-22	27
155	Type I interferons in Sjögren's syndrome. <b>2013</b> , 12, 558-66	71
154	Lupus sistémico y dermatomiositis infantil. <b>2013</b> , 48, 1-13	
153	Pathogenesis of myositis: Lessons learned from animal studies. <b>2013</b> , 8, 170-178	1
152	Lupus systémique et dermatomyosites de l'enfant. <b>2013</b> , 8, 1-13	

151	Current perspectives on systems immunology approaches to rheumatic diseases. <b>2013</b> , 65, 1407-17	15
150	A critical role for immature muscle precursors in myositis. <b>2013</b> , 9, 438-42	16
149	Was gibt es Neues bei Myopathien?. <b>2013</b> , 40, 242-248	
148	Juvenile dermatomyositis. <b>2013</b> , 113, 1457-63	8
147	Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. <b>2013</b> , 210, 355-74	45
146	Pharmacogenomics and translational simulations to bridge indications for an anti-interferon- $\beta$ receptor antibody. <b>2013</b> , 93, 483-92	39
145	Recent advances in juvenile idiopathic inflammatory myopathies. <b>2014</b> , 26, 671-8	14
144	Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. <b>2014</b> , 26, 724-41	13
143	Use of microarrays in the clinical practice of pediatric rheumatology: the future is now?. <b>2014</b> , 26, 585-91	2
142	Personalized Healthcare in Autoimmune Diseases. <b>2014</b> , 51-71	1
141	Application of Translational Science to Clinical Development. <b>2014</b> , 1-21	
140	MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders. <b>2014</b> , 969-1078	
139	Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. <b>2014</b> , 36, 495-517	34
138	A phase 1b clinical trial evaluating sifalimumab, an anti-IFN- $\beta$ monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. <b>2014</b> , 73, 256-62	113
137	Dermatomyositis as a complication of interferon- $\beta$ therapy: a case report and review of the literature. <b>2014</b> , 34, 1319-22	5
136	Progress and prognosis in juvenile dermatomyositis. <b>2014</b> , 9, 567-584	
135	Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. <b>2015</b> , 12, 29	13
134	Using proteomic and genomic methods to understand JDM. <b>2015</b> , 38, 150-6	1

133	Using Transcriptional Signatures to Assess Immune Cell Function: From Basic Mechanisms to Immune-Related Disease. <b>2015</b> , 427, 3356-67	4
132	Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. <b>2015</b> , 56, 31-9	21
131	The role of type I interferons and other cytokines in dermatomyositis. <b>2015</b> , 73, 319-25	26
130	Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis. <b>2015</b> , 35, 411-20	16
129	Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis. <b>2015</b> , 285, 161-8	15
128	The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. <b>2015</b> , 52, 189-95	58
127	Endotoxin tolerance in monocytes can be mitigated by $\beta$ -interferon. <b>2015</b> , 98, 651-9	8
126	Monocyte enhancers are highly altered in systemic lupus erythematosus. <b>2015</b> , 7, 921-35	20
125	Immunological biomarkers in dermatomyositis. <i>Current Rheumatology Reports</i> , <b>2015</b> , 17, 68	4-9 11
124	Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. <b>2015</b> , 11, 1265-75	20
123	The genetics of human autoimmune disease: A perspective on progress in the field and future directions. <b>2015</b> , 64, 1-12	54
122	Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?. <b>2015</b> , 351, h5079	41
121	Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. <b>2016</b> , 31, 389-96	12
120	Immunological Biomarkers for Patient Stratification. <b>2016</b> , 327-361	
119	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. <b>2016</b> , 84, 100-9	18
118	Autoimmune Myopathies. <b>2016</b> , 22, 1852-1870	9
117	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. <b>2016</b> , 55, 1673-80	10
116	Autoimmune muscle disease. <b>2016</b> , 133, 467-84	9

115	Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. <b>2016</b> , 94, 1111-1127	68
114	Update on the pharmacological treatment of adult myositis. <b>2016</b> , 280, 63-74	33
113	Bioinformatics analysis of gene expression profiles of dermatomyositis. <b>2016</b> , 14, 3785-90	2
112	Juvenile Dermatomyositis. <b>2016</b> , 351-383.e18	20
111	Cutaneous dermatomyositis in the era of biologicals. <b>2016</b> , 38, 113-21	9
110	MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis. <b>2016</b> , 43, 161-8	14
109	The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. <b>2016</b> , 576, 14-21	65
108	Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. <b>2017</b> , 52, 81-87	12
107	Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. <b>2017</b> , 35, 337-370	44
106	Causes and consequences of endoplasmic reticulum stress in rheumatic disease. <b>2017</b> , 13, 25-40	59
105	Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice. <b>2017</b> , 199, 1041-1050	34
104	Treatment of Juvenile Dermatomyositis: An Update. <b>2017</b> , 19, 423-434	17
103	Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. <b>2017</b> , 56, 1662-1675	50
102	A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1- $\beta$ . <b>2017</b> , 177, 590-593	3
101	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. <b>2017</b> , 37, 123-132	94
100	Biologics for idiopathic inflammatory myopathies. <b>2017</b> , 29, 645-651	5
99	Using multi-omics methods to understand dermatomyositis/polymyositis. <b>2017</b> , 16, 1044-1048	26
98	Cytokines as Orchestrators of Skeletal Muscle Tissue Maintenance and the Inflammation Associated With Acquired Autoimmune and Hereditary Muscle Diseases. <b>2017</b> , 149-162	

97	Risk factors and disease mechanisms in myositis. <b>2018</b> , 14, 255-268		62
96	Development of a Validated Interferon Score Using NanoString Technology. <b>2018</b> , 38, 171-185		69
95	Update on outcome assessment in myositis. <b>2018</b> , 14, 303-318		55
94	Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. <b>2018</b> , 57, 671-676		6
93	Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis. <b>2018</b> , 70, 134-145		25
92	Targeting interferons as a strategy for systemic sclerosis treatment. <b>2018</b> , 195, 45-54		9
91	A child with severe juvenile dermatomyositis treated with ruxolitinib. <b>2018</b> ,		
90	Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2951	8.4	27
89	The Vasculopathy of Juvenile Dermatomyositis. <b>2018</b> , 6, 284		21
88	A child with severe juvenile dermatomyositis treated with ruxolitinib. <b>2018</b> , 141, e80		37
87	Epigenetics of Systemic Lupus Erythematosus. <b>2018</b> , 133-148		
86	Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. <b>2018</b> , 20, 37		2
85	Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 422	8.4	78
84	Overall Downregulation of mRNAs and Enrichment of H3K4me3 Change Near Genome-Wide Association Study Signals in Systemic Lupus Erythematosus: Cell-Specific Effects. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 497	8.4	10
83	CD19CD24CD38 B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- $\beta$ <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1372	8.4	34
82	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. <b>2018</b> , 141, 1609-1621		104
81	Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. <b>2019</b> , 45, 410-420		20
80	Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon. <b>2019</b> , 17, 56		6

79	Identification of distinctive interferon gene signatures in different types of myositis. <b>2019</b> , 93, e1193-e1204		39
78	Immunomics in Pediatric Rheumatic Diseases. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 111	4.9	1
77	Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. <b>2019</b> , 249, 215-226		15
76	A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 638	8.4	1
75	Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 83-89	3.5	5
74	Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1028	8.4	25
73	Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. <b>2019</b> , 71, 1377-1390		28
72	Gene Expression Meta-Analysis Reveals Concordance in Gene Activation, Pathway, and Cell-Type Enrichment in Dermatomyositis Target Tissues. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 657-666	3.5	9
71	Interferon-signature in idiopathic inflammatory myopathies. <b>2019</b> , 31, 634-642		15
70	Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. <b>2020</b> , 16, 31-43		4
69	Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 584254	8.4	2
68	How Retroviruses and Retrotransposons in Our Genome May Contribute to Autoimmunity in Rheumatological Conditions. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 593891	8.4	5
67	Clinical trials and novel therapeutics in dermatomyositis. <b>2020</b> , 25, 213-228		3
66	Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies. <b>2020</b> , 39, 2171-2178		3
65	Statin-Associated Muscle Symptoms. <i>Contemporary Cardiology</i> , <b>2020</b> ,	0.1	
64	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. <b>2020</b> , 22, 69		17
63	A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. <b>2021</b> , 84, 1160-1162		2
62	Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. <b>2021</b> , 73, 858-865		27

61	Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology. <b>2021</b> , 73, 1062-1072	1
60	Inflammatory milieu of muscle biopsies in juvenile dermatomyositis. <b>2021</b> , 41, 77-85	2
59	Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. <b>2021</b> , 11, 7144-7158	3
58	Investigation of type I interferon responses in ANCA-associated vasculitis. <b>2021</b> , 11, 8272	1
57	The Vasculopathy of Juvenile Dermatomyositis: Endothelial Injury, Hypercoagulability, and Increased Arterial Stiffness. <b>2021</b> , 73, 1253-1266	4
56	The role of interferons type I, II and III in myositis: A review. <b>2021</b> , 31, e12955	8
55	IgG and IgA autoantibodies against L1 ORF1p expressed in granulocytes correlate with granulocyte consumption and disease activity in pediatric systemic lupus erythematosus. <b>2021</b> , 23, 153	0
54	Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence. <b>2021</b> , 7, 258-271	1
53	Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation. <b>2021</b> , 227, 108732	1
52	Long-Term Risk of Autoimmune Diseases other than Systemic Lupus Erythematosus in Cutaneous Lupus Erythematosus-Alone Patients: A 10-Year Nationwide Cohort Study. <b>2021</b> , 1-9	1
51	Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. <b>2021</b> , 33, 371-377	1
50	Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. <b>2021</b> ,	2
49	SIGLEC1 enables straightforward assessment of type I interferon activity in inflammatory myopathies.	0
48	JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. <b>2021</b> , 19, 146	2
47	Musculoskeletal system. <b>2021</b> , 541-559	
46	Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus. <b>2020</b> , 5,	20
45	Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. <b>2011</b> , 6, e24828	48
44	Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. <b>2012</b> , 7, e29161	104

43	Polymyositis and dermatomyositis: Disease spectrum and classification. <b>2012</b> , 57, 366-70		9
42	Inherited Autoinflammatory Syndromes. <b>2021</b> ,		1
41	Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1 $\alpha$ antibodies. <b>2021</b> ,		0
40	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 911-925	11.5	5
39	Juvenile Dermatomyositis. <b>2009</b> , 201-209		
38	Outcomes and Assessment for Inflammatory Muscle Disease. <b>2009</b> , 253-276		
37	The Inflammatory Milieu. <b>2009</b> , 29-53		1
36	Juvenile Dermatomyositis. <b>2009</b> , 55-86		
35	Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects. <b>2011</b> , 105-125		1
34	Dermatomyositis. <b>2014</b> , 349-365		
33	A Unified Molecular Signature of Systemic Lupus Erythematosus Revealed by Integrated, Multi-Cohort Transcriptomic Analysis.		
32	Management Considerations: Juvenile Dermatomyositis. <b>2020</b> , 285-298		
31	Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. <i>Annals of Blood</i> , <b>2020</b> , 5,	0.6	2
30	Statin-Associated Autoimmune Myopathy and Other Forms of Myositis. <i>Contemporary Cardiology</i> , <b>2020</b> , 169-178	0.1	
29	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 679030	4.9	
28	The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. <i>Lancet Rheumatology</i> , <b>2021</b> ,	14.2	1
27	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 86	51.1	7
26	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.. <i>RMD Open</i> , <b>2022</b> , 8,	5.9	0

25	Refractory Alopecia Universalis Associated with Dermatomyositis Successfully Treated with Tofacitinib.. <i>Modern Rheumatology Case Reports</i> , <b>2022</b> ,	0.4	1
24	Identification of Latent Diagnostic Biomarkers and Biological Pathways in Dermatomyositis Based on WGCNA.. <i>Journal of Oncology</i> , <b>2021</b> , 2021, 1920111	4.5	
23	Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
22	data_sheet_1.PDF. <b>2018</b> ,		
21	data_sheet_2.PDF. <b>2018</b> ,		
20	table_1.PDF. <b>2018</b> ,		
19	Data_Sheet_1.PDF. <b>2020</b> ,		
18	Data_Sheet_1.DOCX. <b>2018</b> ,		
17	Altered Gut Microbiome in Patients With Dermatomyositis. <i>ACR Open Rheumatology</i> ,	3.5	0
16	Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis. <i>ACR Open Rheumatology</i> ,	3.5	0
15	Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis. <i>Aging</i> ,	5.6	
14	Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists. <i>Frontiers in Medicine</i> , 9,	4.9	0
13	Multi-Modal Single-Cell Sequencing Identifies Cellular Immunophenotypes Associated With Juvenile Dermatomyositis Disease Activity. <i>Frontiers in Immunology</i> , 13,	8.4	0
12	Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis. <i>Current Rheumatology Reports</i> ,	4.9	1
11	New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review.		0
10	Activation of cGAS-STING pathway [A possible cause of myofiber atrophy/necrosis in dermatomyositis and immune-mediated necrotizing myopathy.		0
9	Juvenile dermatomyositis treated with methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil: A retrospective case series study.		0
8	Tumorscreening obligatorisch. <b>2022</b> , 70, 886-895		0

- 7 Targeting type I interferons in systemic lupus erythematosus. 13, ○
- 6 Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis. ○
- 5 Current Concepts and Future Prospects in Immune-Mediated Myopathies. **2023**, 161-189 ○
- 4 Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. **2023**, 9, e002864 ○
- 3 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. ard-2022-223628 ○
- 2 Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. **2023**, 9, e002876 1
- 1 Single-cell profiling of peripheral blood and muscle cells reveals inflammatory features of juvenile dermatomyositis. 11, ○